Earnings summaries and quarterly performance for Immunome.
Executive leadership at Immunome.
Clay Siegall
Detailed
President and Chief Executive Officer
CEO
BL
Bob Lechleider
Detailed
Chief Medical Officer
JH
Jack Higgins
Detailed
Chief Scientific Officer
KH
Kinney Horn
Detailed
Chief Business Officer
MR
Max Rosett
Detailed
Chief Financial Officer
PT
Phil Tsai
Detailed
Chief Technical Officer
RS
Roee Shahar
Detailed
Executive Vice President, Commercial
SS
Sandra Stoneman
Detailed
Chief Legal Officer and General Counsel
Board of directors at Immunome.
Research analysts covering Immunome.
Recent press releases and 8-K filings for IMNM.
Immunome Reports Positive Phase III Data for Varegacestat and Provides Pipeline Updates
IMNM
Product Launch
New Projects/Investments
- Immunome's gamma secretase inhibitor, varegacestat, recently reported positive Phase III data in desmoid tumors, achieving a hazard ratio of 0.16. The company plans to submit to the FDA within the next few months.
- Varegacestat is positioned as superior to the competitor Ogsiveo due to a much higher objective response rate (ORR), better pain relief, and once-a-day dosing. The U.S. market opportunity for desmoid tumors includes 1,600 new patients annually and 11,000 prevalence patients seeking therapy.
- The lead antibody-drug conjugate (ADC) program, IM-1021 targeting ROR1, is in dose escalation phase one and has demonstrated objective responses at multiple dose levels. Immunome is expanding clinical work for IM-1021 and sees an accelerated approval opportunity for patients with three or more prior therapies in B-cell lymphomas.
- Immunome also plans to submit 3 Investigational New Drug (IND) applications for solid tumors this year and will soon start clinical trials for its radioligand therapy.
Feb 11, 2026, 2:00 PM
Immunome Reports Positive Phase III Data for Desmoid Tumor Drug and Advances ADC Pipeline
IMNM
New Projects/Investments
Revenue Acceleration/Inflection
- Immunome reported positive Phase III data for its gamma secretase inhibitor, varegacestat, in desmoid tumors late last year (December 2025). The company plans to submit a New Drug Application (NDA) to the FDA within the next few months (from February 2026), aiming for a 4-month timeline.
- The U.S. market opportunity for desmoid tumors includes 1,600 new patients annually and 11,000 prevalence patients seeking therapy. Immunome believes that 3,000 patients could generate a billion-dollar market for the drug, based on competitor pricing.
- Varegacestat is positioned as superior to the currently marketed Ogsiveo (nirogacestat), which has a $320 million annualized run rate, due to a much higher objective response rate (ORR), better pain relief, and a once-a-day dosing regimen.
- Immunome's lead Antibody-Drug Conjugate (ADC) program, IM-1021 (targeting ROR1), is in dose escalation Phase 1 and has shown objective responses at multiple dose levels. The company sees an accelerated approval opportunity for IM-1021 in lymphoma.
- Immunome plans to submit three Investigational New Drug (IND) applications for solid tumors this year (2026). Additionally, their radioligand therapy has been cleared by the FDA and will soon begin clinical trials.
Feb 11, 2026, 2:00 PM
Immunome Reports Positive Phase III Data for Varegacestat and Plans NDA Submission
IMNM
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Immunome's gamma secretase inhibitor, varegacestat, recently reported positive Phase III data in desmoid tumors, achieving a hazard ratio of 0.16.
- The company plans to submit the NDA for varegacestat to the FDA within the next few months (from February 2026), targeting a substantial market opportunity with approximately 11,000 prevalence patients in the US annually.
- Immunome's lead ADC program, IM-1021 (targeting ROR1), is in Phase I clinical trials and has demonstrated objective responses at multiple dose levels.
- The company is expanding its IM-1021 work and plans to submit three new INDs for solid tumors this year (2026), in addition to a radioligand therapy starting clinical trials soon.
Feb 11, 2026, 2:00 PM
Immunome Provides Pipeline Update at J.P. Morgan Healthcare Conference
IMNM
New Projects/Investments
Product Launch
Guidance Update
- Immunome reported positive top-line data for its oral drug, AL102, a gamma-secretase inhibitor for desmoid tumors, in December, achieving a hazard ratio of 0.16, 56% objective response rate, and 83% median tumor reduction. The company plans to submit the New Drug Application (NDA) for AL102 in the second quarter of 2026.
- The company's ROR1 ADC (IM-1021) has demonstrated objective responses at multiple dose levels in Phase I clinical trials, leading to expanded trial sites, with clinical data anticipated to be released this year.
- Immunome's pipeline includes a FAP radioligand, which has been cleared by the FDA to begin clinical trials within the next couple of months, and the company plans to submit three Investigational New Drug (IND) applications for solid tumor ADCs in 2026 and three more in 2027.
- The company maintains a strong cash position, with funds projected to last into 2028.
Jan 14, 2026, 6:30 PM
Immunome Provides Update on Oncology Pipeline and Milestones
IMNM
Product Launch
New Projects/Investments
Guidance Update
- Immunome plans to submit a New Drug Application (NDA) for Varegacestat in 2Q 2026, following positive Phase 3 topline data for desmoid tumors, which demonstrated a Progression-Free Survival Hazard Ratio of 0.16 (p<0.0001) and a Confirmed Objective Response Rate of 56%.
- The company is advancing a deep ADC pipeline, including IM-1021 (ROR1 ADC) with initial lymphoma data expected in 2026, and three first-in-class solid tumor ADCs (IM-1617, IM-1340, IM-1335) with Investigational New Drug (IND) submissions planned for Early, Mid, and Late 2026, respectively.
- Immunome's IM-3050 FAP Radiotherapy is entering Phase 1, with the First Patient In expected Early 2026.
- The company's financial runway is expected to extend into 2028.
Jan 14, 2026, 6:30 PM
Immunome Highlights Positive AL102 Data and Pipeline Expansion at J.P. Morgan Conference
IMNM
Product Launch
New Projects/Investments
Guidance Update
- Immunome reported positive top-line data for its AL102 (varegacestat) program for desmoid tumors in December. Key results include an objective response rate of 56% and a median tumor reduction of 83%. The company plans to submit a New Drug Application (NDA) for AL102 in the second quarter of this year (2026) and anticipates potential approval this calendar year.
- The company's ROR1 ADC (IM-1021) has demonstrated objective responses at multiple dose levels in Phase 1 clinical trials for B lymphomas, leading to an expansion of clinical sites. Immunome also has a FAP radioligand that has received FDA clearance and is expected to start clinical trials within the next couple of months.
- Immunome plans significant pipeline expansion, aiming to submit three Investigational New Drug (IND) applications this year (2026) and three for next year (2027), all targeting solid tumors with its advanced ADC platform.
- The company maintains a strong financial position, with enough cash projected to extend into 2028.
Jan 14, 2026, 6:30 PM
Immunome Provides Pipeline Update and AL102 NDA Submission Timeline at J.P. Morgan Healthcare Conference
IMNM
Product Launch
New Projects/Investments
Guidance Update
- Immunome reported positive top-line data in December for AL102 (varegacestat), an oral gamma-secretase inhibitor for desmoid tumors, demonstrating a hazard ratio of 0.16, an objective response rate of 56%, and a median tumor reduction of 83%. The company plans to submit a New Drug Application (NDA) for AL102 in the second quarter of 2026.
- The company's ROR1 ADC (IM-1021) has shown objective responses at multiple dose levels in Phase 1 clinical trials for B lymphomas, with clinical data expected to be released this year. Immunome is also expanding its ADC pipeline with three new solid tumor ADC INDs planned for 2026 and three for 2027.
- Immunome's FAP radioligand has been cleared by the FDA and is expected to start clinical trials within the next couple of months.
- The company maintains a strong cash position that extends into 2028. By the end of 2026, Immunome anticipates potentially having seven drugs in clinical development and one drug on the market.
Jan 14, 2026, 6:30 PM
Immunome Announces Pricing of Public Offering of Common Stock
IMNM
- Immunome, Inc. (IMNM) priced an underwritten public offering of 18,625,000 shares of its common stock at $21.50 per share.
- The offering is expected to generate approximately $400 million in gross proceeds for Immunome.
- Underwriters have a 30-day option to purchase up to an additional 2,793,750 shares of common stock.
- The offering is anticipated to close on December 18, 2025.
Dec 17, 2025, 1:16 AM
Immunome Announces Proposed Public Offering of Common Stock
IMNM
- Immunome, Inc. announced a proposed underwritten public offering to issue and sell $400 million of its common stock.
- The company expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock.
- The proposed offering is being made pursuant to a shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (SEC) on February 13, 2024.
- Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC, and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering.
Dec 15, 2025, 9:01 PM
Immunome announces positive Phase 3 Ringside trial results for AL102 in desmoid tumors
IMNM
Product Launch
New Projects/Investments
- Immunome reported positive top-line results from its Ringside phase 3 study of AL102 for desmoid tumors, with the trial meeting all primary and secondary endpoints.
- Key efficacy data for AL102 include a progression-free survival (PFS) hazard ratio of 0.16, an objective response rate (ORR) of 56%, and a median best tumor volume reduction of 83%.
- AL102, an oral gamma secretase inhibitor, demonstrated a manageable safety profile consistent with its drug class and is positioned as a potential best-in-class treatment.
- Immunome plans to meet with the FDA in early 2026 and submit a New Drug Application (NDA) in the second quarter of 2026.
- The company is advancing commercial preparations to target the approximately 11,000 actively managed desmoid tumor patients in the U.S..
Dec 15, 2025, 1:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more